What is the role of delayed intensification therapy in the treatment of pediatric acute lymphoblastic leukemia (ALL)?

Updated: Jan 03, 2019
  • Author: Vikramjit S Kanwar, MBBS, MBA, MRCP(UK), FAAP; Chief Editor: Jennifer Reikes Willert, MD  more...
  • Print
Answer

Delayed intensification, is a repeat of the first two months of induction and consolidation in high-risk and very-high-risk ALL protocols that includes some new agents (substituting dexamethasone for prednisone, doxorubicin for daunorubicin, and 6-thioguanine for 6-MP and repeating others). The goal is to eliminate residual drug-resistant cells. Pioneered by Dr Riehm and the BFM group, this phase was found to be beneficial for patients in all risk groups, including standard-risk and low-risk ALL.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!